Biodesix, Inc. Q3 2025 Earnings Recap

BDSX Q3 2025 November 4, 2025

Get alerts when BDSX reports next quarter

Biodesix reported strong third-quarter results for 2025, achieving a 20% increase in revenue and improved gross margins, while laying the groundwork for future growth in personalized diagnostics.

Earnings Per Share Beat

$-1.16 vs $-1.60 est.

+27.5% surprise

Revenue Miss

21768000 vs 26250000 est.

-17.1% surprise

Market Reaction

1-Day +19.87%

5-Day +21.92%

30-Day +30.6%

See BDSX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue growth accelerated to 20% year-over-year, indicating robust demand for diagnostic tests.
Gross margins improved by 400 basis points to 81%, reflecting operational effectiveness.
Adjusted EBITDA enhanced by 18%, signaling progress towards profitability in Q4.
Tests ordered from primary care surged 75% YOY, as the company expands its market strategy to enhance lung cancer diagnostics.
Average revenue per test increased by 7% from Q2, supported by successful market access initiatives.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BDSX on AllInvestView.